Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.250
+0.003 (1.05%)
At close: Dec 20, 2024, 4:00 PM
0.257
+0.006 (2.56%)
After-hours: Dec 20, 2024, 6:58 PM EST
Company Description
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies.
Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system.
The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Eterna Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Sanjeev Luther |
Contact Details
Address: 1035 Cambridge Street, Suite 18A Cambridge, Massachusetts 02141 United States | |
| Phone | 212 582 1199 |
| Website | eternatx.com |
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082209 |
| ISIN Number | US1140822099 |
| Employer ID | 31-1103425 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President and Director |
| Sandra M. Gurrola | Principal Financial and Accounting Officer and Senior Vice President of Finance |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Dorothy J. Clarke | General Counsel and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 424B3 | Prospectus |
| Nov 18, 2024 | 424B3 | Prospectus |
| Nov 18, 2024 | 424B3 | Prospectus |
| Nov 15, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 14, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 13, 2024 | UPLOAD | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 29, 2024 | 8-K | Current Report |